Publications by authors named "Christopher D Payne"

Claim this Profile
P
Pharmacokinetic Bridging Between an Autoinjector and a Prefilled Syringe Following Subcutaneous Administration of Mirikizumab in Healthy Participants.
Xin Zhang, Yuki Otani, Christopher D Payne, Nathan J Morris, Laiyi Chua

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy Participants.
Yuki Otani, Christopher D Payne, Edward V Loftus, Geert D'Haens, Shomron Ben Horin

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies.
Gerald Chun-To So, Ying Grace Li, Stephen D Hall, Jenny Chien, Christopher D Payne

Clin Pharmacol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Comparability and Safety Between Original and Citrate-Free Mirikizumab Formulations for Subcutaneous Injections: Results from Three Clinical Trials.
Yuki Otani, Brian G Feagan, Geert R D'Haens, Rodrigo Escobar, Nathan J Morris, Christopher D Payne

Adv Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials.
Sanjay Chabra, B J Gill, Gaia Gallo, Danting Zhu, Celine Pitou, Christopher D Payne

Adv Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous Injection Site Pain of Formulation Matrices.
Galen H Shi, Karthik Pisupati, Jonathan G Parker, Vincent J Corvari, Christopher D Payne

Pharm Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.
Xia Zhao, Xiao Yan Sheng, Christopher D Payne, Xin Zhang, Feng Wang

Clin Pharmacol Drug Dev· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition of [C]LY2606368 following intravenous administration in patients with advanced and/or metastatic solid tumours.
Enaksha R Wickremsinhe, Scott M Hynes, Christopher D Payne, Yingying Guo, Kenneth C Cassidy

Xenobiotica· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.
Maria M Posada, Ellen A Cannady, Christopher D Payne, Xin Zhang, James A Bacon

Clin Transl Sci· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Joseph A Jakubowski, Chunmei Zhou, Kenneth J Winters, D Richard Lachno, Jo Howard, Christopher D Payne

Platelets· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.
Christopher D Payne, Mark A Deeg, Melanie Chan, Lai Hock Tan, Elizabeth Smith LaBell

Br J Clin Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Iron limitation modulates ocean acidification effects on southern ocean phytoplankton communities.
Clara J M Hoppe, Christel S Hassler, Christopher D Payne, Philippe D Tortell, Björn Rost

PLoS One· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
Joseph A Jakubowski, Chunmei Zhou, Stipo Jurcevic, Kenneth J Winters, D Richard Lachno, Christopher D Payne

Thromb Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
Joseph A Jakubowski, Chunmei Zhou, David S Small, Kenneth J Winters, D Richard Lachno, Christopher D Payne

Br J Clin Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of "rebound" platelet hyperreactivity following cessation of prasugrel.
Joseph A Jakubowski, Ying G Li, Christopher D Payne, David S Small, Kenneth J Winters

Thromb Haemost· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.
David S Small, Ying G Li, C Steven Ernest, John H April, Nagy A Farid, Christopher D Payne

J Clin Pharmacol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
David S Small, Nagy A Farid, Christopher D Payne, Christopher S Konkoy, Joseph A Jakubowski

Clin Pharmacokinet· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Joseph A Jakubowski, Ying G Li, David S Small, Christopher D Payne, Molly E Tomlin

J Cardiovasc Pharmacol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
David S Small, Prajakti Kothare, Eunice Yuen, D Richard Lachno, Ying G Li, Christopher D Payne

Eur J Clin Pharmacol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
David S Small, Christopher D Payne, Prajakti Kothare, Eunice Yuen, Fanni Natanegara

Clin Ther· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
David S Small, Rebecca E Wrishko, C Steven Ernest, Lan Ni, Kenneth J Winters, Christopher D Payne

Drugs Aging· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Ying G Li, Lan Ni, John T Brandt, David S Small, Christopher D Payne

Platelets· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Nagy A Farid, David S Small, Christopher D Payne, Joseph A Jakubowski, John T Brandt

Pharmacotherapy· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
David S Small, Nagy A Farid, Ying G Li, C Steven Ernest, Christopher D Payne

Curr Med Res Opin· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Christopher D Payne, Ying G Li, John T Brandt, Joseph A Jakubowski, David S Small

Platelets· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis